Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study. — CFSMEATLAS
Multi-Site Clinical Assessment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (MCAM): Design and Implementation of a Prospective/Retrospective Rolling Cohort Study.
Unger, Elizabeth R, Lin, Jin-Mann S, Tian, Hao et al. · American journal of epidemiology · 2017 · DOI
Quick Summary
Researchers created a large study called MCAM to better understand ME/CFS by collecting standardized health information from patients across seven U.S. clinics. They also enrolled healthy people and patients with similar illnesses for comparison. The study tracked patients over time, collected samples for future research, and documented how doctors were treating ME/CFS patients, aiming to identify different types of ME/CFS and find tests that could help diagnosis.
Why It Matters
This study addresses a critical gap in ME/CFS research by systematically collecting standardized clinical data across multiple expert clinics, enabling researchers to understand disease heterogeneity and identify potential biomarkers. For patients, this work provides a foundation for developing better diagnostic tools, understanding disease subtypes, and validating outcome measures that could improve clinical care and future treatment research.
Observed Findings
471 patients with ME/CFS were successfully enrolled in stage 1 from 7 specialty clinics across the United States.
Healthy comparison groups and disease comparison groups (patients with similar illnesses) were enrolled alongside ME/CFS patients.
Standardized questionnaires were implemented to measure key illness domains and patient-reported outcomes.
Biospecimens were collected for future hypothesis testing, including morning cortisol profiles.
Clinical management practices, prescribed medications, and diagnostic testing patterns were systematically documented.
Inferred Conclusions
Expert clinician-diagnosed ME/CFS patients show heterogeneity across multiple clinical sites, suggesting the disease may involve multiple subtypes or presentations requiring further characterization.
Systematic collection of standardized measures is feasible and necessary for identifying which clinical assessments best distinguish ME/CFS from comparison conditions.
Future analysis of collected biospecimens and clinical data may reveal biomarkers or subphenotypes that clarify ME/CFS pathophysiology and improve diagnostic accuracy.
Remaining Questions
Which specific questionnaires and clinical measures most effectively distinguish ME/CFS from comparison groups and predict clinical outcomes?
What This Study Does Not Prove
This methods paper does not present clinical findings or prove any treatments work. It does not establish what causes ME/CFS, confirm any biomarkers as diagnostic, or demonstrate differences between subgroups. The study's reliance on expert clinician diagnosis rather than standardized diagnostic criteria may affect generalizability, and long-term outcomes data were not yet available at publication.